Fed. Circ. Won't Revive Amarin's Vascepa Patents
The Federal Circuit on Thursday shot down Amarin Pharma Inc.'s appeal of a lower court order invalidating patents for its heart drug Vascepa, handing a win to a duo of generic-drug...To view the full article, register now.
Already a subscriber? Click here to view full article